Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 700 publications
Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database.
Journal: Science progress
Published: October 15, 2025
Real-World Outcomes in Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer in Argentina: A Multicenter Retrospective Study (GAOT-ALK001).
Journal: JCO global oncology
Published: October 03, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 16, 2025
Update on the Treatment of Non-Small Cell Lung Carcinoma (NSCLC).
Journal: Journal of clinical medicine
Published: September 07, 2025
Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
Journal: Journal of managed care & specialty pharmacy
Published: August 30, 2025
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 08, 2025
Lorlatinib Achieved Rapid CNS Response in an 81-Year-Old NSCLC Patient With Performance Status Deterioration.
Journal: Respirology case reports
Published: July 28, 2025
Patient-derived organoid facilitating personalized medicine in non-small cell lung cancer: two case reports.
Journal: Frontiers in oncology
Published: July 28, 2025
Severe skin toxicity and early progression following neoadjuvant ensartinib and surgery in anaplastic lymphoma kinase-positive locally advanced lung cancer: a case report.
Journal: Frontiers in pharmacology
Published: July 25, 2025
Sex differences in cardiotoxicity of anaplastic lymphoma kinase inhibitors: An analysis of the FDA Adverse Event Reporting System.
Journal: Oncology
Published: July 24, 2025
A Decade of Treating ALK-Rearranged Non-Small Cell Lung Cancer in a Lower Middle-Income Country: Changing Patterns and Improving Survival.
Journal: Oncology and therapy
Published: July 16, 2025
Last Updated: 10/31/2025